

22 September 2020

[REDACTED]

By email: [REDACTED]
Ref: H202006656

Dear [REDACTED]

Response to your request for official information

Thank you for your request under the Official Information Act 1982 (the Act) on 28 August 2020 to the Medicinal Cannabis Agency (the Agency) for information regarding applications for assessment of a new medicinal cannabis product.

I will respond to each part of your request in turn.

1. For the period 1 April 2020 to 1 August 2020, the number of applications for assessment of a new medicinal cannabis product received by the Medicinal Cannabis Agency, and the number of applicants these relate to.

For the period from 1 April 2020 to 1 August 2020, the Agency received nine applications, from three applicants.

2. The following dates for each such application:
a. the date the application was received

Please refer to table one below.

Date	Number of applications received
28 June 2020	1
29 June 2020	7
8 July 2020	1

b. the date screening commenced

The applications screening commences when the applicant has paid the fee for the initial check of the application.

As at 1 August 2020, payment of the initial check fee for one application was received and screening had commenced for this application on 27 July 2020.

c. the date screening was completed.

As at 1 August 2020, no applications had completed the screening process.

d. The date assessment commenced (for applications that passed screening)

Assessment of applications commences when the applicant has paid the assessment fee. As at 1 August 2020, no applications had completed the screening process, and therefore no product assessments had commenced.

e. The date an assessment report was issued.

f. The date the application was determined

As at 1 August 2020, no assessment reports were issued and no applications were determined.

3. The number of products that have been assessed as meeting the minimum quality standard.

As at 1 August 2020, no products had been assessed as meeting the minimum quality standards.

4. the number of applications rejected at screening

As at 1 August 2020, no applications had been rejected at the screening stage.

I trust this information fulfils your request. Under section 28(3) of the Act you have the right to ask the Ombudsman to review any decisions made under this request.

Please note that this response, with your personal details removed, may be published on the Medsafe website.

Yours sincerely

A handwritten signature in blue ink, appearing to read 'Chris James', is written over a light blue horizontal line.

Chris James
Licensing Authority
Medicinal Cannabis Agency